Cerebral Small Vessel Diseases, Subcortical Vascular Dementia
Conditions
Keywords
DL-3-n-butylphthalide, vascular dementia, cerebral small vessel disease, cognitive function, cerebral blood flow
Brief summary
This is a 48-week, double-blind, randomized, placebo-controlled study. Sixty-four patients are randomly assigned to take NBP (600mg per day) or placebo for 48 weeks, with 32 patients in each treatment group. Anti-dementia treatment-naive patients meet the inclusion/exclusion criteria are enrolled. Patients are assigned to NBP will take 200mg tid daily. Patients are visited at baseline, as well as 4, 12, 24, 36, 48weeks after baseline. Safety data is recorded until an additional 30 days after the last treatment (48 weeks). The primary outcomes include cognitive function and activities of daily living (ADL). All subjects are assessed at baseline, 4w, 12w,24w, 36w intermittent visit and 48w endpoint with the Auditory Verbal Learning Test (AVLT), the Brief Visuospatial Memory Test-Revised (BVMT-R), the Symbol Digit Modalities Test (SDMT), the Trail Making Test-A/B (TMT-A/B), the Benton Judgment of Line Orientation (JLO), the verbal fluency test, the Boston Naming Test (BNT), the Controlled Oral Word Association Test (COWAT), the Stroop test, the Mini-Mental State Examination (MMSE), the Montreal Cognitive Assessment (MoCA) and the ADL. The secondary outcomes include the global function and behavioral and psychological symptoms of dementia (BPSD), which are evaluated with the Clinical Dementia Rating (CDR) and the Neuropsychiatric Inventory (NPI), respectively. Independent raters who are blinded to patients' distribution are assigned to assess the participants. The exploratory outcomes are markers of vascular regulation, including circulating endothelial progenitor cells (EPCs), white matter hyperintensities (WMH) on MRI, cerebral blood flow (CBF) measured with transcranial Doppler (TCD) and arterial spin labeling (ASL) MRI, and parameters of carotid duplex ultrasonic (CDU). In addition, apolipoprotein E (APOE) polymorphism and plasma biomarkers are also detected. Safety are assessed at each visit.
Interventions
DRUGNBP
NBP soft capsules
DRUGPlacebos
Soft capsules manufactured to mimic NBP
Sponsors
Tianjin Medical University General Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Intervention model description
double-blind, randomized, placebo controlled study
Eligibility
Sex/Gender
ALL
Age
50 Years to 85 Years
Healthy volunteers
No
Inclusion criteria
1. Patients meet the criteria of major neurocognitive disorder in the fifth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5); 2. Patients aged with 50-80 years, years of education no less than 3, an MMSE range of 15\ 26, an MoCA \< 26, an Hamilton Depression Scale (HAMD) \< 17; 3. The MRI (one research dedicated machine 3.0 T) features satisfy subcortical small vessel disease, including (1) multiple (\>=3) supratentorial subcortical lacunes (3-20 mm in diameter), with/without white matter hyperintensities (WMH) of any degree; (2) moderate to severe WMH (score\>= 2 according to the Fazekas rating scale in either periventricular region or deep white matter) with/without lacunes; (3) one or more strategically located subcortical small infarcts in the deep grey matters; 4. Patients or legal representative should sign the informed consent and have a reliable caregiver.
Exclusion criteria
1. Cognitive impairment caused by other central nervous system diseases, such as AD, dementia with Lewy body, frontal-temporal lobe degeneration, etc; 2. Cognitive impairment due to other conditions, such as severe depression, vitamin B 12 deficiency, abnormal thyroid function, etc; 3. Alcoholism, drug abuse or other conditions influenced the evaluation of cognition; 4. Patients unable to undertake MRI assessment. 5. Patients with a history of other severe disease such as epilepsy, myocardial infarction or heart failure will be excluded; 6. Administration of other investigational drugs, psychotropic drugs, drugs with psychiatric side effects, and oral anticoagulants are not allowed
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Activity of daily living (ADL) at endpoint and change from baseline | 48 weeks post-dose and change from baseline | ADL is used to evaluate activities of daily living. |
| Trail Making Test-A (TMT-A) at endpoint and change from baseline | 48 weeks post-dose and change from baseline | TMT-A is used to assess information processing speed. Lower score indicates better performance. |
| TMT-B at endpoint and change from baseline | 48 weeks post-dose and change from baseline | TMT-B is used to assess executive function. Lower score indicates better performance. |
| Stroop test at endpoint and change from baseline | 48 weeks post-dose and change from baseline | Stroop test is used to assess executive function. Higher score indicates better performance. |
| Benton Judgment of Line Orientation (JLO) at endpoint and change from baseline | 48 weeks post-dose and change from baseline | JLO is used to assess visuospatial function. Higher score indicates better performance. |
| Verbal fluency test at endpoint and change from baseline | 48 weeks post-dose and change from baseline | Verbal fluency test is used to evaluate language function. Higher score indicates better performance. |
| Boston Naming Test (BNT) at endpoint and change from baseline | 48 weeks post-dose and change from baseline | BNT is used to evaluate language function. Higher score indicates better performance. |
| Controlled Oral Word Association Test (COWAT) at endpoint and change from baseline | 48 weeks post-dose and change from baseline | COWAT is used to evaluate language function. Higher score indicates better performance. |
| Mini-Mental State Examination (MMSE) at endpoint and change from baseline | 48 weeks post-dose and change from baseline | MMSE is used to evaluate global cognition. Higher score indicates better performance. |
| Montreal Cognitive Assessment (MoCA) at endpoint and change from baseline | 48 weeks post-dose and change from baseline | MoCA is used to evaluate global cognition. Higher score indicates better performance. |
| Auditory Verbal Learning Test (AVLT) at endpoint and change from baseline | 48 weeks post-dose and change from baseline | AVLT is used to evaluate verbal learning and memory ability. Higher score indicates better performance. |
| Brief Visuospatial Memory Test-Revised (BVMT-R) at endpoint and change from baseline | 48 weeks post-dose and change from baseline | BVMT-R is used to evaluate spatial memory ability. Higher score indicates better performance. |
| Digital span (DS) at endpoint and change from baseline | 48 weeks post-dose and change from baseline | DS is used to assess attention. Higher score indicates better performance. |
| Symbol Digit Modalities Test (SDMT) at endpoint and change from baseline | 48 weeks post-dose and change from baseline | SDMT is used to assess information processing speed. Higher score indicates better performance. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Neuropsychiatric Inventory (NPI) at endpoint and change from baseline | 48 weeks post-dose and change from baseline | NPI is used to evaluate behavioral and psychological symptoms of dementia (BPSD). |
| Global function at endpoint and change from baseline | 48 weeks post-dose and change from baseline | Clinical Dementia Rating (CDR) is used to evaluate global function. |
Other
| Measure | Time frame | Description |
|---|---|---|
| Transcranial Doppler (TCD) at endpoint and change from baseline | 48 weeks post-dose and change from baseline | TCD is used to measure cerebral blood flow. |
| Carotid duplex ultrasonic (CDU) at endpoint and change from baseline | 48 weeks post-dose and change from baseline | CDU is used to evaluate cerebral blood flow and arteriosclerosis. |
| Arterial spin labeling (ASL) MRI at endpoint and change from baseline | 48 weeks post-dose and change from baseline | Arterial spin labeling (ASL) is used to measure cerebral blood flow. |
| White matter hyperintensities (WMH) at endpoint and change from baseline | 48 weeks post-dose and change from baseline | The extent and volume of WMH are analyzed on MRI. |
| Geriatric Depression Scale (GDS) at endpoint and change from baseline | 48 weeks post-dose and change from baseline | GDS is used to evaluate depressive symptoms. |
| Hamilton Depression Scale (HAMD) at endpoint and change from baseline | 48 weeks post-dose and change from baseline | HAMD is used to evaluate depressive symptoms. |
| Regulation of endothelial progenitor cell at endpoint and change from baseline | 48 weeks post-dose and change from baseline | Circulating endothelial progenitor cell (EPC) is detected with flow cytometry. |
Countries
China
Contacts
Primary ContactNan Zhang, MD, PhD
Backup ContactMengya Xing, MD, PhD
Outcome results
None listed